氟哌噻吨美利曲辛联合常规药物治疗难治性功能性肠病的疗效观察

目的观察氟哌噻吨美利曲辛联合常规消化道药物治疗难治性功能性肠病的临床疗效。方法选择符合罗马标准Ⅲ的难治性功能性肠病患者60例，给予常规性治疗（如解痉剂、促动力药、益生菌等）联合氟哌噻吨美利曲辛方案，比较患者治疗前后临床症状、抑郁焦虑状态和生活质量评分。结果60例患者完成6周随访，治疗总有效率为96．6％，总的症状严重度分值（3．78±1．6）分VS（1．98±0．78）分]明显降低（P〈0．01），单项症状严重程度及发作频率评分均明显减少（P〈0．05）。抑郁评分（62．68±5．94）VS（47．7±16．06）分，P〈0．01]和焦虑评分（61．35±6．86）vs（46．57±14．36）分，P〈0．01]均显著下降。结论氟哌噻吨美利曲辛联合常规药物治疗难治性功能性肠病可以明显改善患者的肠道症状，控制抑郁情绪，显著提高生活质量。

Therapeutic efficacy of flupentixol and melitracen combined with conventional medicine in patients with refractory functional bowel disorders

Objective To explove the therapeutic efficacy of flupentixol and melitracen combined with conventional medicine in patients with refractory functional bowel disorders（FBD）. Method 60 patients with FBD, defined by the Rome Ill, were given flupentixol and melitracen combined with conventional medicine （such as antispasmodic agents,prokinetic drugs,probiotics et al）. The clinical outcomes were evaluated by scales changes of clinical symptom, depression, anxiety, and quality of life at the beginning and 6 weeks after treatment. Result All 60 cases completed therapy and 6 weeks follow-up visit. The overall response rate was 96.6%. The general severity score of symptoms（3.78 ± 1.6 vs 1.98 ±0. 78） were subsided significantly（P 〈0.01 ）. The score of the severity and frequency of single symptom were subsided （ P 〈 0.05, respectively）. The score of depression （ 62.68 ± 5.94 vs 47.74 ± 16.06 ,P 〈 0.01 ） and score of anxiety（61.35 ± 6.86 vs 46.57 ± 14.36 ,P 〈 0.01 ） were significantly. Conclusion The therapeutic efficacy of flupentixol and melitracen combined with conventional medicine in patients with refractory functional bowel disorders is explicit. The symptoms, depression and the quality of life can be all improved significantly.